The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; none of the 6 sources its claims cite is checked for support yet.
The bacterial genotoxin colibactin promotes colon tumor growth by modifying the tumor microenvironment
Open accessAbstract
The gut microbiota is suspected to promote colorectal cancer (CRC). Escherichia coli are more frequently found in CCR biopsies than in healthy mucosa; furthermore, the majority of mucosa-associated E. coli isolated from CCR harbors the pks genomic island (pks+ E. coli) that is responsible for the synthesis of colibactin, a genotoxic compound. We have recently reported that transient contact of a few malignant cells with colibactin-producing E. coli increases tumor growth in a xenograft mouse model. Growth is sustained by cellular senescence that is accompanied by the production of growth factors. We demonstrated that cellular senescence is a consequence of the pks+ E. coli-induced alteration of p53 SUMOylation, an essential post-translational modification in eukaryotic cells. The underlying mechanisms for this process involve the induction of miR-20a-5p expression, which targets SENP1, a key protein in the regulation of the SUMOylation process. These results are consistent with the expression of SENP1, miR-20a-5p and growth factors that are observed in a CRC mouse model and in human CCR biopsies colonized by pks+ E. coli. Overall, the data reveal a new paradigm for carcinogenesis in which pks+ E. coli infection induces cellular senescence characterized by the production of growth factors that promote the proliferation of uninfected cells and, subsequently, tumor growth.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
Colibactin-producing *E. coli* (pks+ *E. coli*) induce cellular senescence in intestinal epithelial cells via a c-Myc/miR-20a-5p/SENP1 axis that increases SUMO-conjugated p53, and the resulting senescence-associated secretory phenotype (notably HGF) promotes proliferation of uninfected cells and tumor growth. The authors propose that pks+ *E. coli* modify the tumor microenvironment to favor colon tumor promotion.
Key findings
- Transient infection of HCT116 xenografts in nude mice at low MOI (20) increased tumor growth and Ki67-positive cells, whereas high MOI (100) decreased tumor growth, consistent with tumor dormancy from massive cell-cycle arrest (n = 5/group; *P* < 0.05).
- Conditioned medium from pks+ *E. coli*-infected cells increased proliferation of uninfected cells to a degree similar to medium with 10% fetal bovine serum; this was reproduced across Int-407, HCT8, Caco-2, HT-29, HCT116 and non-transformed IEC-6 cells.
- pks+ *E. coli* induced senescence (SA-β-gal, phospho-p53, p21^Cip, Rb accumulation, decreased E2F-1) with increased HGF, FGF and GM-CSF; tumors at day 10 post-implantation showed an ~3-fold increase in the percentage of senescent cells versus pks− controls.
- An HGF pathway inhibitor (and neutralizing antibodies) abrogated the pro-proliferative activity of conditioned medium and significantly blocked xenograft growth; mechanistically, pks+ *E. coli* induced c-Myc, which drove miR-20a-5p, which bound the SENP1 3′-UTR and reduced SENP1, increasing SUMO1-conjugated p53.
- In the AOM/DSS model, colonization with a clinical pks+ *E. coli* strain significantly increased colon tumor number versus the isogenic pks mutant, without affecting inflammatory score or tumor size; γH2Ax, miR-20a-5p, SA-β-gal, p21^Cip and HGF pathway activation were increased. Human colon adenocarcinoma biopsies colonized by pks+ *E. coli* showed the same signature (high γH2Ax, miR-20a-5p, senescence markers, HGF mRNA and activated HGF receptors; decreased SENP1-expressing cells), differentiating them from pks−-colonized tumors by redundancy analyses.
Methods
- Xenograft model: HCT116 cells (2 × 10⁶) subcutaneously injected into nude mice and infected for 3 hours with pks+ *E. coli* or isogenic pks− *E. coli* at MOI 20 or 100; tumor size monitored over time.
- In vitro assays: conditioned medium transfer to measure proliferation of uninfected cells across multiple intestinal epithelial lines; SA-β-gal, senescence protein profiles, growth factor expression, SUMOylation patterns, miR-20a-5p/SENP1 reporter and transfection experiments, and inhibitor/neutralizing antibody treatments.
- In vivo validation: AOM/DSS (azoxymethane/dextran sodium sulfate) CRC mouse model colonized with a clinical pks+ *E. coli* strain versus its isogenic pks mutant, plus analysis of human colon adenocarcinoma biopsies colonized by pks+ versus pks− *E. coli* (including redundancy analyses).
Limitations
- Stated: pks+ *E. coli*-induced senescence was also observed in p53−/− cells, suggesting pathways other than p53 signaling may be involved.
- Stated: no increase in tumor size was observed with pks+ *E. coli* in the AOM/DSS model in immunocompetent mice, possibly because senescent tumors generate an immune response that constrains expansion; the authors note the promoting effect on intestinal tumor size may be difficult to observe.
- Stated: the study focused on colibactin as the sole toxin affecting the cell cycle, but clinical pks+ *E. coli* frequently also produce CNF1, whose impact on CRC remains to be explored; overall understanding of the cancer-promoting potential of pks+ *E. coli* remains limited and clinical consequences need clarification.
- Evident from the text: several supporting results are described as "unpublished data" (e.g., high-MOI growth decrease, SUMOylation patterns, anacardic acid and SENP1 overexpression effects), and the role of the dormancy-type interaction in intestinal tumors "remains to be assessed."
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 6 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, using a reporter assay, we demonstrated that miR-20a-5p binds to the SENP1 mRNA 3'-UTR.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“pksC E. coli-infected cells displayed a modified pattern of SUMO-conjugated proteins compared with pks-E.coliinfected cells or uninfected cells (unpublished data).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“pksC E. coli, in contrast to pks-E.coli, induced a time- dependent and dose-dependent increase in SA-b-gal activity.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of note, the expression levels of FGF, GM-CSF and HGF were also increased in xenografts at 10 d post-pksC E. coli infection compared to xenografts infected with pks-E.coli.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: The subcutaneous xenograft model in immunodeficient mice is a valid model for the effect of pksC E. coli on human colon tumor growth.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interestingly, pksC E. coli-infected cells expressed significantly higher levels of the growth factors HGF, FGF, and GM-CSF than pks-E.coli-infected cells.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, transfection of cells with mature miR-20a-5p decreased SENP1 expression at both the mRNA and protein levels.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Interestingly, over-expression of SENP1, unlike overexpression of an inactive SENP1, significantly decreased the number of senescent cells induced by pksC E. coli infection, confirming the role of SENP1 in pksC E. coli-induced senescence.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this model, a single and transient exposure of xenografts to pksC E. coli at a multiplicity of infection (MOI) of 20 was associated with an increase in tumor growth and Ki67positive cell numbers, suggesting that pksC E. coli enhance cell proliferation (Fig. 1A).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: The subcutaneous xenograft model in immunodeficient mice is a valid model for the effect of pksC E. coli on human colon tumor growth.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“An HGF pathway inhibitor, in contrast to vehicle or other growth factor inhibitors abrogated the pro-proliferative activity of CM in vitro.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, an anti-miR-20a-5p abrogated pksC E. coli-induced accumulation of SUMO1-conjugated p53 and, consequently, cellular senescence.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 12
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“pksC E. coli did not affect the inflammatory score or the size of the tumors.”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The AOM/DSS mouse model is a valid model for human colorectal cancer promotion by pksC E. coli.
In the paper
“pksC E. coli-infected cells exhibited an accumulation of phospho-p53, p21 Cip , and Retinoblastoma protein as well as a decrease in E2F-1 expression at day 5 post-infection, which correspond to a protein expression profile characteristic of senescent cells.12”
What the sources say
- Not checked yetcites [12] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As observed upon pksC E. coli infection, cells transfected with miR-20a-5p produced significant levels of HGF, and their CM induced the proliferation of untransfected cells.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Accordingly, we observed an accumulation of SUMO1-conjugated p53, which is known to drive cellular senescence.17 This accumulation was associated with a decrease in SENP1 expression, a key enzyme involved in the control of the SUMOylation process.17”
What the sources say
- Not checked yetcites [17] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Accordingly, we observed that pksC E. coli infection, which is known to induce DNA damage, 9,10 induced c-Myc expression and its binding to the miR-20a-5p promoter.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Finally, time-course experiments showed that pksC E. coli induced c-Myc expression 3 d after infection, followed by modifications of miR-20a-5p and SENP1 expression levels 2 d later.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Transfection of pksC E. coli-infected cells with c-Myc siRNA strongly reduced the expression of miR20a-5p, increased the expression of SENP1, reduced the level of SUMO-conjugated p53, decreased the number of pksC E. coli-induced senescent cells and consequently abolished the pro-proliferative effect of the CM derived from those cells.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The DNA damage marker gH2Ax, the miR-20a-5p expression level and senescence markers (SA-b-gal activity and p21 cip expression) were significantly increased in tumors isolated from mice colonized by the clinical pksC E. coli strain compared with those isolated from mice colonized by the corresponding isogenic mutant.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The AOM/DSS mouse model is a valid model for human colorectal cancer promotion by pksC E. coli.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As observed in the AOM/DSS mouse model, human biopsies colonized by pksC E. coli harbored high expression levels of gH2Ax, miR-20a-5p, senescence markers (SA-b-gal, p21 cip ), and HGF mRNA and activated HGF receptors, as well as a decrease in the number of SENP1-expressing cells.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“pksC E. coli activate the miR-20a-5p/SENP1/senescence/HGF pathway (Fig. 1B) in human and murine colon adenocarcinomas and therefore may contribute to CCR development.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our findings suggest that colibactin-producing E. coli modulate the tumor microenvironment by inducing the secretion of several growth factors from senescent cells, which can promote tumor growth.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The subcutaneous xenograft model in immunodeficient mice is a valid model for the effect of pksC E. coli on human colon tumor growth.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Consequently, colibactinproducing bacteria can modulate the tumor microenvironment to favor the emergence of senescent cells, which may also affects tumor promotion and cancer progression via the secretion of growth factors.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper relies on this without support.
The pks genomic island is responsible for the synthesis of colibactin, a genotoxic compound.
“the majority of mucosa-associated E. coli isolated from CCR harbors the pks genomic island (pksC E. coli) that is responsible for the synthesis of colibactin, a genotoxic compound.”
The paper relies on this without support.
The subcutaneous xenograft model in immunodeficient mice is a valid model for the effect of pksC E. coli on human colon tumor growth.
“The promotion of tumor growth was clearly observed in the subcutaneous xenograft model using immunodeficient mice.”
The paper relies on this without support.
The AOM/DSS mouse model is a valid model for human colorectal cancer promotion by pksC E. coli.
“To confirm the reliability of our findings, we explored the impact of a clinical pksC E. coli strain in an AOM/DSS (azoxymethane/dextran sodium sulfate) CRC mouse model.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“in several mouse models, other colibactin-producing E. coli have been observed to promote the development of colorectal cancer [125–131]”
From Selection, Comparative Genomics, and Potential Probiotic Features of Escherichia coli 5C, a pks-Negative Strain Isolated from Healthy Infant Donor Feces (2026) · cites this paper as [129]
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C. D., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,468
Structure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
c-Myc-regulated microRNAs modulate E2F1 expression
O'Donnell, K. A., Wentzel, E. A., Zeller, K. I., Dang, C. V., & Mendell, J. T. (2005) · Nature · doi:10.1038/nature03677 · Cited by 2,347
Intestinal inflammation targets cancer-inducing activity of the microbiota
Arthur, J. C., Perez-Chanona, E., Mühlbauer, M., Tomkovich, S., Uronis, J. M., Fan, T.-J., Campbell, B. J., Abujamel, T., Dogan, B., Rogers, A. B., et al. (2012) · Science · doi:10.1126/science.1224820 · Cited by 2,263
Four faces of cellular senescence
Rodier, F., & Campisi, J. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201009094 · Cited by 2,070
Senescence in premalignant tumours
Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A. J., Barradas, M., Benguría, A., Zaballos, A., Flores, J. M., Barbacid, M., et al. (2005) · Nature · doi:10.1038/436642a · Cited by 1,482
Escherichia coli Induces DNA Double-Strand Breaks in Eukaryotic Cells
Nougayrède, J.-P., Homburg, S., Taieb, F., Boury, M., Brzuszkiewicz, E., Gottschalk, G., Buchrieser, C., Hacker, J., Dobrindt, U., & Oswald, E. (2006) · Science · doi:10.1126/science.1127059 · Cited by 1,188
The signals and pathways activating cellular senescence
Ben-Porath, I., & Weinberg, R. A. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.10.013 · Cited by 1,046
Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells
Cuevas-Ramos, G., Petit, C. R., Marcq, I., Boury, M., Oswald, E., & Nougayrède, J.-P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001261107 · Cited by 855
Flagged first, then by citations
Research works printed but not linked: 2
- Matsui S, 2010, Int J Oncol, 37, 289
- 10.1016/s0962-8924(01)02151-1 · DOI · Paper page
Cited by
Sorted by citations
The microbiome, cancer, and cancer therapy
Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V., & Wargo, J. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0377-7 · Cited by 1,200
Cullin, N., Azevedo Antunes, C., Straussman, R., Stein-Thoeringer, C. K., & Elinav, E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.08.006 · Cited by 578
Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells
Ang, Q. Y., Alexander, M., Newman, J. C., Tian, Y., Cai, J., Upadhyay, V., Turnbaugh, J. A., Verdin, E. M., Hall, K. D., Leibel, R. L., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.027 · Cited by 589
A history of exploring cancer in context
Maman, S., & Witz, I. P. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0006-7 · Cited by 502
Yu, L. C. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0483-8 · Cited by 419
Matson, V., Chervin, C. S., & Gajewski, T. F. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.11.041 · Cited by 385
Lam, M. M. C., Wyres, K. L., Duchêne, S., Wick, R. R., Judd, L. M., Gan, Y., Hoh, C.-H., Archuleta, S., Molton, J. S., Kalimuddin, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05114-7 · Cited by 357
Dzutsev, A., Badger, J. H., Perez-Chanona, E., Roy, S., Salcedo, R., Smith, C. K., & Trinchieri, G. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052133 · Cited by 302
The colibactin warhead crosslinks DNA
Vizcaino, M. I., & Crawford, J. M. (2015) · Nature Chemistry · doi:10.1038/nchem.2221 · Cited by 247
Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics
Lynch, J. P., Goers, L., & Lesser, C. F. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.02.002 · Cited by 240
Colibactin: More Than a New Bacterial Toxin
Faïs, T., Delmas, J., Barnich, N., Bonnet, R., & Dalmasso, G. (2018) · Toxins · doi:10.3390/toxins10040151 · Cited by 227
Self-citationYin, C., Noratto, G. D., Fan, X., Chen, Z., Yao, F., Shi, D., & Gao, H. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.116942 · Cited by 217
Microbial dysbiosis in the gut drives systemic autoimmune diseases
Mousa, W. K., Chehadeh, F., & Husband, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.906258 · Cited by 216
Curty, G., de Carvalho, P. S., & Soares, M. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010222 · Cited by 193
The microbiome and the hallmarks of cancer
Fulbright, L. E., Ellermann, M., & Arthur, J. C. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006480 · Cited by 164
Xia, X., Wu, W. K. K., Wong, S. H., Liu, D., Kwong, T. N. Y., Nakatsu, G., Yan, P. S., Chuang, Y., Chan, M. W. Y., Coker, O. O., et al. (2020) · Microbiome · doi:10.1186/s40168-020-00847-4 · Cited by 155
The Rise of Gastrointestinal Cancers as a Global Phenomenon: Unhealthy Behavior or Progress?
Jardim, S. R., de Souza, L. M. P., & de Souza, H. S. P. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20043640 · Cited by 157
Dysbiosis, malnutrition and enhanced gut-lung axis contribute to age-related respiratory diseases
Saint‐Criq, V., Lugo‐Villarino, G., & Thomas, M. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101235 · Cited by 152
Intestinal bacteria and colorectal cancer: etiology and treatment
Dougherty, M. W., & Jobin, C. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2185028 · Cited by 145
Lucafò, M., Curci, D., Franzin, M., Decorti, G., & Stocco, G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.772101 · Cited by 130
Colon Carcinogenesis: The Interplay Between Diet and Gut Microbiota
Loke, Y. L., Chew, M. T., Ngeow, Y. F., Lim, W. W.-D., & Peh, S. C. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.603086 · Cited by 138
Whisner, C. M., & Aktipis, A. (2019) · Current Nutrition Reports · doi:10.1007/s13668-019-0257-2 · Cited by 131
Turesky, R. J. (2018) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2018.718 · Cited by 130
Dash, S., Aydın, Y., Widmer, K., & Nayak, L. (2020) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s221187 · Cited by 131
Sadrekarimi, H., Gardanova, Z. R., Bakhshesh, M., Ebrahimzadeh, F., Yaseri, A. F., Thangavelu, L. P., Hasanpoor, Z., Zadeh, F. A., & Kahrizi, M. S. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03492-7 · Cited by 131
Lopès, A., Billard, E., Casse, A. H., Villéger, R., Véziant, J., Roche, G., Carrier, G., Sauvanet, P., Briat, A., Pagès, F., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32920 · Cited by 125
The roles of microbial products in the development of colorectal cancer: a review
Fang, Y., Yan, C., Zhao, Q., Xu, J., Liu, Z., Gao, J., Zhu, H., Dai, Z., Wang, D., & Tang, D. (2021) · Bioengineered · doi:10.1080/21655979.2021.1889109 · Cited by 122
E. coli and colorectal cancer: a complex relationship that deserves a critical mindset
Wassenaar, T. M. (2018) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2018.1481013 · Cited by 119
Armstrong, H., Bording‐Jorgensen, M., Dijk, S., & Wine, E. (2018) · Cancers · doi:10.3390/cancers10030083 · Cited by 122
Alterations in the gut microbiota and metabolite profiles of thyroid carcinoma patients
Feng, J., Zhao, F., Sun, J., Lin, B., Zhao, L., Liu, Y., Jin, Y., Li, S., Li, A., & Wei, Y. (2018) · International Journal of Cancer · doi:10.1002/ijc.32007 · Cited by 116
Iyadorai, T., Mariappan, V., Vellasamy, K. M., Wanyiri, J. W., Roslani, A. C., Lee, G. K., Sears, C. L., & Vadivelu, J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228217 · Cited by 124
The Enterobacterial Genotoxins: Cytolethal Distending Toxin and Colibactin
Taieb, F. E., Petit, C. R., Nougayrède, J., & Oswald, É. (2016) · EcoSal Plus · doi:10.1128/ecosalplus.esp-0008-2016 · Cited by 123
A catch‐22: Interleukin‐22 and cancer
Hernández, P. P., Gronke, K., & Diefenbach, A. (2017) · European Journal of Immunology · doi:10.1002/eji.201747183 · Cited by 117
The roles of the gut microbiota–miRNA interaction in the host pathophysiology
Li, M., Chen, W., & Wang, Y. (2020) · Molecular Medicine · doi:10.1186/s10020-020-00234-7 · Cited by 111
Snider, E. J., Compres, G., Freedberg, D. E., Khiabanian, H., Nobel, Y. R., Stump, S., Uhlemann, A., Lightdale, C. J., & Abrams, J. A. (2019) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-19-0008 · Cited by 108
Unboxing the molecular modalities of mutagens in cancer
Kumari, S., Sharma, S., Advani, D., Khosla, A., Kumar, P., & Ambasta, R. K. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-16726-w · Cited by 115
Doocey, C. M., Finn, K., Murphy, C. P., & Guinane, C. M. (2022) · BMC Microbiology · doi:10.1186/s12866-022-02465-6 · Cited by 98
Alves, N. D. O., Dalmasso, G., Nikitina, D., Vaysse, A., Ruez, R., Ledoux, L., Pédron, T., Bergsten, E., Boulard, O., Autier, L., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2320291 · Cited by 99
Self-citationLu, M., Chen, Y.-T., Chiang, M., Wang, Y., Hsiao, P.-Y., Huang, Y.-J., Lin, C.-T., Cheng, C., Liang, C.-L., & Lai, Y. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00103 · Cited by 101
Parvimonas micra as a putative non-invasive faecal biomarker for colorectal cancer
Löwenmark, T., Löfgren‐Burström, A., Zingmark, C., Eklöf, V., Dahlberg, M. L., Wai, S. N., Larsson, P. G., Ljuslinder, I., Edin, S., & Palmqvist, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-72132-1 · Cited by 96
Non-enzymatic covalent modifications: a new link between metabolism and epigenetics
Zheng, Q., Maksimovic, I., Upad, A., & David, Y. (2020) · Protein & Cell · doi:10.1007/s13238-020-00722-w · Cited by 93
MicroRNAs in Tumor Cell Metabolism: Roles and Therapeutic Opportunities
Pedroza‐Torres, A., Romero-Cordoba, S. L., Justo-Garrido, M., Salido-Guadarrama, I., Rodríguez‐Bautista, R., Montaño, S., Muñiz-Mendoza, R., Arriaga-Canon, C., Fragoso‐Ontiveros, V., Álvarez-Gómez, R. M., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01404 · Cited by 93
Perillo, F., Amoroso, C., Strati, F., Giuffrè, M. R., Díaz‐Basabe, A., Lattanzi, G., & Facciotti, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155389 · Cited by 88
Colibactin-driven colon cancer requires adhesin-mediated epithelial binding
Jans, M., Kolata, M., Blancke, G., D’Hondt, A., Gräf, C., Ciers, M., Sze, M., Thiran, A., Petta, I., Andries, V., et al. (2024) · Nature · doi:10.1038/s41586-024-08135-z · Cited by 84
Tumor microbiome – an integral part of the tumor microenvironment
Čierniková, S., Ševčíková, A., Števurková, V., & Mego, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1063100 · Cited by 86
Fidelle, M., Yonekura, S., Picard, M., Cogdill, A. P., Hollebecque, A., Roberti, M. P., & Zitvogel, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.600886 · Cited by 87
ClbS Is a Cyclopropane Hydrolase That Confers Colibactin Resistance
Tripathi, P., Shine, E. E., Healy, A. R., Kim, C. S., Herzon, S. B., Bruner, S. D., & Crawford, J. M. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b09971 · Cited by 87
A framework for how environment contributes to cancer risk
Hochberg, M., & Noble, R. (2017) · Ecology Letters · doi:10.1111/ele.12726 · Cited by 86
Shining a Light on Colibactin Biology
Dougherty, M. W., & Jobin, C. (2021) · Toxins · doi:10.3390/toxins13050346 · Cited by 85
A Mechanistic Model for Colibactin-Induced Genotoxicity
Healy, A. R., Nikolayevskiy, H., Patel, J. R., Crawford, J. M., & Herzon, S. B. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b10354 · Cited by 78
Subversion of host genome integrity by bacterial pathogens
Chumduri, C., Gurumurthy, R. K., Zietlow, R., & Meyer, T. F. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.100 · Cited by 81
Straková, N., Kořená, K., & Karpíšková, R. (2021) · Toxicon · doi:10.1016/j.toxicon.2021.04.007 · Cited by 79
The gut microbiome and efficacy of cancer immunotherapy
Roviello, G., Iannone, L. F., Bersanelli, M., Mini, E., & Catalano, M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107973 · Cited by 77
The gut microbiota and aging: interactions, implications, and interventions
Gyriki, D., Nikolaidis, C. G., Bezirtzoglou, E., Voidarou, C. C., Stavropoulou, E., & Tsigalou, C. (2025) · Frontiers in Aging · doi:10.3389/fragi.2025.1452917 · Cited by 80
The Gut–Vascular Barrier as a New Protagonist in Intestinal and Extraintestinal Diseases
Tommaso, N. D., Santopaolo, F., Gasbarrini, A., & Ponziani, F. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021470 · Cited by 74
Barrett's esophagus is associated with a distinct oral microbiome
Snider, E. J., Compres, G., Freedberg, D. E., Giddins, M. J., Khiabanian, H., Lightdale, C. J., Nobel, Y. R., Toussaint, N. C., Uhlemann, A.-C., & Abrams, J. A. (2018) · Clinical and Translational Gastroenterology · doi:10.1038/s41424-018-0005-8 · Cited by 72
Véziant, J., Villéger, R., Barnich, N., & Bonnet, M. (2021) · Cancers · doi:10.3390/cancers13092215 · Cited by 76
Microbiota and Cancer: The Emerging Beneficial Role of Bifidobacteria in Cancer Immunotherapy
Longhi, G., van Sinderen, D., Ventura, M., & Turroni, F. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.575072 · Cited by 72
Wei, X., Wang, F., Tan, P., Huang, H., Wang, Z., Xie, J., Wang, L., Liu, D., & Hu, Z. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107148 · Cited by 72
Implications of gut microbiota-mediated epigenetic modifications in intestinal diseases
Zhang, Q., Liu, Y., Li, Y., Bai, G., Pang, J., Wu, M., Li, J., Zhao, X., & Xia, Y. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2508426 · Cited by 73
Bian, X., Plaza, A., Zhang, Y., & Müller, R. (2015) · Chemical Science · doi:10.1039/c5sc00101c · Cited by 70
Chattopadhyay, I., Gundamaraju, R., Jha, N. K., Gupta, P. K., Dey, A., Mandal, C. C., & Ford, B. M. (2022) · Disease Markers · doi:10.1155/2022/2941248 · Cited by 67
Escherichia coli ClbS is a colibactin resistance protein
Bossuet‐Greif, N., Dubois, D., Petit, C. R., Tronnet, S., Martín, P., Bonnet, R., Oswald, É., & Nougayrède, J. (2015) · Molecular Microbiology · doi:10.1111/mmi.13272 · Cited by 74
Self-citationThe Genotoxin Colibactin Shapes Gut Microbiota in Mice
Tronnet, S., Floch, P., Lucarelli, L., Gaillard, D., Martín, P., Sérino, M., & Oswald, É. (2020) · mSphere · doi:10.1128/msphere.00589-20 · Cited by 71
Impact of microbiota in colorectal carcinogenesis: lessons from experimental models
Yu, L. C., Wei, S., & Ni, Y. (2018) · Intestinal Research · doi:10.5217/ir.2018.16.3.346 · Cited by 63
Gut Microbiota and Colon Cancer: A Role for Bacterial Protein Toxins?
Fiorentini, C., Carlini, F., Germinario, E. A. P., Maroccia, Z., Travaglione, S., & Fabbri, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176201 · Cited by 63
Nutraceuticals in colorectal cancer: A mechanistic approach
Rossi, M., Mirbagheri, S., Keshavarzian, A., & Bishehsari, F. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.06.027 · Cited by 61
Early settlers: which E. coli strains do you not want at birth?
Secher, T., Brehin, C., & Oswald, E. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00091.2016 · Cited by 58
The Polyamine Spermidine Modulates the Production of the Bacterial Genotoxin Colibactin
Chagneau, C. V., Garcie, C., Bossuet‐Greif, N., Tronnet, S., Brachmann, A. O., Piel, J., Nougayrède, J., Martín, P., & Oswald, É. (2019) · mSphere · doi:10.1128/msphere.00414-19 · Cited by 65
Promotion and induction of liver cancer by gut microbiome-mediated modulation of bile acids
Jia, B., & Jeon, C. O. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007954 · Cited by 55
Microbiota in cancer: current understandings and future perspectives
Yao, Y., Zhu, Y., Chen, K., Chen, J., Li, Y., Li, D., & Wei, P. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02335-3 · Cited by 56
Abuzeyad, O. H., El‐Khawaga, A. M., Tantawy, H., & El-Sayed, M. A. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.135787 · Cited by 50
Iron Homeostasis Regulates the Genotoxicity of Escherichia coli That Produces Colibactin
Tronnet, S., Garcie, C., Rehm, N., Dobrindt, U., Oswald, É., & Martín, P. (2016) · Infection and Immunity · doi:10.1128/iai.00659-16 · Cited by 59
Yu, G., Sun, Y. J., Zhang, D., & Zhang, P. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0992-x · Cited by 49
Dumont-Leblond, N., Veillette, M., Racine, C., Joubert, P., & Duchaine, C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249832 · Cited by 49
Pu, Y., Yi, Q., Zhao, F., Wang, H., Cai, W., & Cai, S. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0340-3 · Cited by 48
RetractedDomain-Targeted Metabolomics Delineates the Heterocycle Assembly Steps of Colibactin Biosynthesis
Trautman, E. P., Healy, A. R., Shine, E. E., Herzon, S. B., & Crawford, J. M. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b00659 · Cited by 48
Gut Microbiota–MicroRNA Interactions in Intestinal Homeostasis and Cancer Development
Nikolaieva, N., Ševčíková, A., Omelka, R., Martiniaková, M., Mego, M., & Čierniková, S. (2022) · Microorganisms · doi:10.3390/microorganisms11010107 · Cited by 47
Genotoxins: The Mechanistic Links between Escherichia coli and Colorectal Cancer
Wang, Y., & Fu, K. (2023) · Cancers · doi:10.3390/cancers15041152 · Cited by 51
Morgan, R. N., Saleh, S. E., Farrag, H. A., & Aboulwafa, M. (2019) · Gut Pathogens · doi:10.1186/s13099-019-0304-y · Cited by 48
Retracteddos Reis, S. A., da Conceição, L. L., & Pelúzio, M. D. C. G. (2019) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001049 · Cited by 46
Uropathogenic E. coli induces DNA damage in the bladder
Chagneau, C. V., Massip, C., Bossuet‐Greif, N., Fremez, C., Motta, J., Shima, A., Besson‐Fournier, C., Faouder, P. L., Cénac, N., Roth, M., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009310 · Cited by 50
The gastrointestinal microbiota and its role in oncogenesis
Lam, S. Y., Yu, J. Q., Wong, S. H., Peppelenbosch, M. P., & Fuhler, G. M. (2017) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2017.09.010 · Cited by 46
Escherichia coli and Colorectal Cancer: Unfolding the Enigmatic Relationship
Rezaee, M. A., Nouri, R., Hasani, A., Shirazi, K. M., Alivand, M. R., Sepehri, B., Sotoodeh, S., & Hemmati, F. (2021) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201022666210910094827 · Cited by 47
The Gut Microbiome Advances Precision Medicine and Diagnostics for Inflammatory Bowel Diseases
Mousa, W. K., & Ali, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011259 · Cited by 50
Sarshar, M., Scribano, D., Marazzato, M., Ambrosi, C., Aprea, M. R., Aleandri, M., Pronio, A., Longhi, C., Nicoletti, M., Zagaglia, C., et al. (2017) · Microbial Pathogenesis · doi:10.1016/j.micpath.2017.10.009 · Cited by 43
Growth rate alterations of human colorectal cancer cells by 157 gut bacteria
Taddese, R., Garza, D. R., Ruiter, L. N., de Jonge, M. I., Belzer, C., Aalvink, S., Nagtegaal, I. D., Dutilh, B. E., & Boleij, A. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1799733 · Cited by 43
The pks island: a bacterial Swiss army knife? Colibactin: beyond DNA damage and cancer
Chagneau, C. V., Payros, D., Tang-Fichaux, M., Auvray, F., Nougayrède, J., & Oswald, É. (2022) · Trends in Microbiology · doi:10.1016/j.tim.2022.05.010 · Cited by 43
Influence of Iron on the Gut Microbiota in Colorectal Cancer
Phipps, O., Al-Hassi, H. O., Quraishi, M. N., Kumar, A., & Brookes, M. (2020) · Nutrients · doi:10.3390/nu12092512 · Cited by 41
López‐Siles, M., Camprubí-Font, C., del Pulgar, E. M. G., Sàbat, M., Busquets, D., Sanz, Y., & Martínez-Medina, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.748839 · Cited by 42
Microbial Colonization Coordinates the Pathogenesis of a Klebsiella pneumoniae Infant Isolate
Pope, J. L., Yang, Y., Newsome, R. C., Sun, W., Sun, X., Ukhanova, M., Neu, J., Issa, J. J., Mai, V., & Jobin, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-39887-8 · Cited by 44
Our Little Friends with Big Roles: Alterations of the Gut Microbiota in Thyroid Disorders
Ejtahed, H., Angoorani, P., Soroush, A., Siadat, S. D., Shirzad, N., Hasani‐Ranjbar, S., & Larijani, B. A. (2019) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530319666190930110605 · Cited by 41
ClbR Is the Key Transcriptional Activator of Colibactin Gene Expression in Escherichia coli
Wallenstein, A., Rehm, N., Brinkmann, M., Selle, M., Bossuet‐Greif, N., Sauer, D., Bunk, B., Spröer, C., Wami, H. T., Homburg, S., et al. (2020) · mSphere · doi:10.1128/msphere.00591-20 · Cited by 45
New Insights into the Relationship between Gut Microbiota and Radiotherapy for Cancer
Li, Z., Ke, X., Dan, Z., Wang, Z., Fang, F., & Li, B. (2022) · Nutrients · doi:10.3390/nu15010048 · Cited by 39
Tang-Fichaux, M., Chagneau, C. V., Bossuet‐Greif, N., Nougayrède, J., Oswald, É., & Branchu, P. (2020) · mSphere · doi:10.1128/msphere.01195-20 · Cited by 45
Examining the gut-liver axis in liver cancer using organoid models
Shek, D., Chen, D., Read, S. A., & Ahlenstiel, G. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.008 · Cited by 39
NF-κB Regulation by Gut Microbiota Decides Homeostasis or Disease Outcome During Ageing
Zhang, S., Paul, S., & Kundu, P. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.874940 · Cited by 40
Dai, H., Han, J., Wang, T., Yin, W., Chen, Y., & Liu, H. (2023) · Natural Product Reports · doi:10.1039/d2np00075j · Cited by 38
Greathouse, K. L., & Choudhury, A. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.05.011 · Cited by 38
Molecular crosstalk between polyphenols and gut microbiota in cancer prevention
Zeb, F., Naqeeb, H., Osaili, T. M. I., Faris, M. E., Ismail, L. C., Obaid, R. S., Naja, F., Radwan, H. M., Hasan, H. A., Hashim, M. S., et al. (2024) · Nutrition Research · doi:10.1016/j.nutres.2024.01.012 · Cited by 39
Metadata
- Authors
- Dalmasso, G., Cougnoux, A., Delmas, J., Darfeuille-Michaud, A., & Bonnet, R.
- Affiliations
- Inserm (FR)
- Corresponding author
- Bonnet, Richard
- Venue
- Gut Microbes
- Publisher
- Informa UK Limited
- Published
- 2014-09-03
- Volume
- 5
- Issue
- 5
- Pages
- 675-680
- ISSN
- 1949-0976 (ISSN-L)
- 1949-0984
- PMC
- PMC4615906
- OpenAlex
- W1964485249
- Semantic Scholar
- 10b0e7d77ac0c96917fb9e7be28852f987ee6021
- Cited by
- 296
- References
- 30
- Citations by year
- 2026: 22 · 2025: 32 · 2024: 27 · 2023: 31 · 2022: 35 · 2021: 39 · 2020: 35 · 2019: 24 · 2018: 18 · 2017: 16 · 2016: 11 · 2015: 5
- FWCI
- 7.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Gut Microbes (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- Institut National de la Santé et de la Recherche Médicale (USC-2018, U1071)
- Ligue Contre le Cancer
- Centre National de la Recherche Scientifique
- Institut National de la Recherche Agronomique (U1071, USC-2018)
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Escherichia coli research studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- colibactin, Escherichia coli, colorectal cancer, tumor microenvironment, cellular senescence, SENP1, miR-20a-5p, growth factors, gut microbiota, carcinogenesis, xenograft mouse model
- MeSH terms
- Animals, Colonic Neoplasms, Cysteine Endopeptidases, Escherichia coli, Models, Biological, Mutagens, Endopeptidases, Peptides, Tumor Suppressor Protein p53, MicroRNAs, Mice, Sumoylation, Tumor Microenvironment, Polyketides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
